八——循证决策在临床上的应用.pptVIP

2. 靶向药物的应用时机 OPTIMAL研究、TORCH研究显示： 究竟一线还是二线使用靶向药物取决于EGFR的突变状态： 对于野生型患者应一线化疗二线靶向治疗， 而对于突变型患者则以一线靶向治疗二线化疗为好。 Residual risk is due to modifiable and non-modifiable risk factors2 Rosuva 10 mg Atorva 10 mg Lova20-40 mg Prava40 mg Simva 10-40 mg Simva 40 mg Atorva 10 mg Prava40 mg Prava40 mg Prava 40 mg Statins Provide Substantial CV Risk Reduction, But Risk for CV Events Remains1 1. Adapted from Chapman et al. Pharmacol Ther. 2010;126:314-345.2. NCEP ATP III. Circulation. 2002;106:3143–3421 例2 N Engl J Med 2006; 354:1264-72 Monoclonal antibodies bound to PCSK9 Clin Th